Form 8-K IDEAYA Biosciences, Inc. For: Sep 23
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
RBC Capital Reiterates Outperform Rating on Ideaya Biosciences (IDYA)
September 24, 2024 6:14 AM EDTRBC Capital analyst Gregory Renza reiterated an Outperform rating and $61.00 price target on Ideaya Biosciences (NASDAQ: IDYA).
The analyst comments "Our key takeaway from IDYA's call this morning is a more refined blueprint for daro's regulatory path with positive ph.II data and the... More
Citi Reiterates Buy Rating on Ideaya Biosciences (IDYA)
September 23, 2024 4:34 PM EDTCiti analyst Yigal Nochomovitz reiterated a Buy rating and $58.00 price target on Ideaya Biosciences (NASDAQ: IDYA).
The analyst comments "The Ph2 neoadjuvant UM data (including the prior IST) were in-line with our expectations for very substantial efficacy reflecting a 61% eye preservation rate among... More
Ideaya Biosciences (IDYA) PT Raised to $48 at Goldman Sachs
September 23, 2024 3:48 PM EDTGoldman Sachs analyst Corinne Jenkins raised the price target on Ideaya Biosciences (NASDAQ: IDYA) to $48.00 (from $47.00) while maintaining a Buy rating.
The analyst comments "DYA announced interim results from an ongoing Ph2 company-sponsored and investigator-sponsored study of darovasertib (daro) in neoadjuvant uveal melanoma (UM). Per the update, 49% (N=49) of patients achieved tumor shrinkage of 30%, while 61% (N=31) in the enucleation-evaluable cohort achieved eye preservation.... More
Ideaya Biosciences (IDYA) PT Lowered to $66 at Stifel
September 23, 2024 3:45 PM EDTStifel analyst Ben Burnett lowered the price target on Ideaya Biosciences (NASDAQ: IDYA) to $66.00 (from $68.00) while maintaining a Buy rating.
The analyst comments "We think the clinical data for darovasertib in the neoadjuvant setting are good, but that the stock... More
BTIG Reiterates Buy Rating on Ideaya Biosciences (IDYA)
September 23, 2024 1:42 PM EDTBTIG analyst Justin Zelin reiterated a Buy rating and $62.00 price target on Ideaya Biosciences (NASDAQ: IDYA).
The analyst comments ": IDYA reported updated data from the co-sponsored trial of darovasertib in neoadjuvant uveal melanoma (UM) and provided details on Ph 3 strategy in this setting. Big picture,... More
